“You don’t need to leave the U.S. to get real stem cell therapy.” – Seth Berge

In this episode of Compound Wisdom, Steve Sood sits down with Seth Berge, founder of Regenerative Revival, to unpack what’s really holding back regenerative medicine—and why the problem isn’t the science, but the system delivering it.

Seth shares his unconventional path from high-ticket direct-to-consumer sales into the stem cell space, revealing how real demand and promising outcomes were being undermined by friction, poor communication, and broken follow-up models. Together, they explore how education-first selling, concierge care, and compliant systems can dramatically improve patient outcomes while still allowing the business to scale.

The conversation dives deep into stem cell myths, why leaving the U.S. for treatment is often unnecessary, and how regulation—when done right—can actually become a competitive advantage. Seth also explains the growing role of IV stem cells and exosomes in wellness, longevity, and inflammation support, along with where the regenerative health industry is heading next.

Takeaways

Friction in healthcare kills trust, outcomes, and conversion
Great medicine often fails because of broken delivery systems
Education-first models outperform traditional clinic selling
Stem cells can be explained without medical jargon
You don’t need to leave the U.S. for legitimate stem cell access
FDA “non-approval” does not mean illegal or ineffective
Cultured and expanded cells overseas carry unknown risks
IV stem cells and exosomes are emerging wellness tools
Concierge, mobile care improves patient experience and scale
Regulation can eliminate bad actors and reward compliant operators

Chapters

00:01 Friction Kills Conversion

02:07 Seth’s Entry Into Stem Cells Through Sales

04:13 Full Rooms, Zero Conversions

05:42 Removing Friction From the Model

06:22 Why Dinner Seminars Still Work

09:12 Stem Cells Explained Simply

11:14 The Overseas Stem Cell Myth

13:47 Cultured Cells vs Non-Manipulated Tissue

15:42 Marketing Limits in the U.S.

17:01 IV Stem Cells and Exosomes

19:31 How Often to Use Stem Cells for Optimization

20:24 Pricing, Access, and Market Maturity

22:30 Helping Med Spas Enter the Space

25:16 Addressing Skepticism and Credibility

28:07 Concierge, At-Home Treatment

30:10 Regulation and the Future of Regenerative Medicine

34:19 Biggest Risks in Telehealth

35:59 Learning From Competitors